Possible Lurasidone-Associated Dose-Dependent QTc Prolongation in First-Episode Psychosis.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 68
- By:
- Publication type:
- Article
Works matching IS 00485764 AND DT 2022 AND VI 52 AND IP 3
Results: 8
1
2
Psychopharmacotherapy of Premenstrual Dysphoric Disorder--New Vistas.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 81
- By:
- Publication type:
- Article
3
New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 72
- By:
- Publication type:
- Article
4
Combining Medication Adherence Support Plus Long-Acting Injectable Antipsychotic Medication: A Post-Hoc Analysis of 3 Pilot Studies.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 41
- By:
- Publication type:
- Article
5
Sleep Deprivation & Amphetamine Induced Psychosis.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 31
- By:
- Publication type:
- Article
6
Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 20
- By:
- Publication type:
- Article
7
Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 8
- By:
- Publication type:
- Article
8
Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses.
- Published in:
- Psychopharmacology Bulletin, 2022, v. 52, n. 3, p. 58
- By:
- Publication type:
- Article